December 13, 2011 -Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin® Program at ASH Annual Meeting
November 15, 2011 - Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
October 19, 2011 - EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
October 19, 2011 - Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin® Pipeline Development
May 23, 2011 - Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin® PRS-080 Hepcidin Antagonist Drug Program
April 12, 2011 - Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin® Therapeutics
April 11, 2011 - Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference
February 22, 2011 - Pieris to Present Interim Data from the Phase I Clinical Trial of
PRS-050 at Molecular Medicine Tri-Conference
January 10, 2011 - Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration
2010
September 28, 2010 - Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics
June 15, 2010 - Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
June 7, 2010 - Pieris AG Appoints Chief Scientific Officer
April 30, 2010 - Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
January 4, 2010 - Pieris Appoints a New CEO
2009
October 9, 2009 - Pieris reports preclinical development progress of its next generation VEGF antagonist
September 15, 2009 - Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
February 3, 2009 - Pieris reports development progress for Anticalin PRS-050, a next generation VEGF antagonist and expands its management team to support program success
2008
July 16, 2008 - Wacker validates scalability of Anticalin production with E.coli secretion technology and will produce Pieris first clinical candidate PRS-050
March, 27, 2008 - Pieris raises Euro 25 M (US 38 M) in Series B financing round led by OrbiMed Advisors LLC
2007
November, 8 2007 - Pieris strengthens its management, as it prepares for the clinical development of PRS-050, an Anticalin-based novel cancer therapy
October, 30 2007 - Pieris and Pepscan to identify GPCR-specific Anticalins using CLIPS™ protein mimicry technology
September, 5 2007 - Pieris validates the use of Anticalins as ophthalmologic biotherapeutics
July, 10 2007 - Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin-based protein product candidate
June, 21 2007 - Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin technology
March, 29 2007 - Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin in preclinical studies